Prasugrel

Generic Name: Prasugrel

Brand Names: Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₀FNO_₃S

CAS Number: 150322-43-3

Unique Ingredient Identifier: 34K66TBT99

Background: Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication: 用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions: Cardiovascular Events

Clinical Trials

Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-02-12

Last Posted Date: 2017-04-04

Lead Sponsor: Tufts Medical Center

Target Recruit Count: 24

Registration Number: NCT01789814

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States

Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome

Phase 3

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2013-01-29

Last Posted Date: 2013-01-29

Lead Sponsor: Gennaro Sardella

Target Recruit Count: 68

Registration Number: NCT01778842

Locations: 🇮🇹
Dept.of Cardiovascular Sciences,Policlinico Umberto I, Rome, Italy

The Elderly ACS II Trial

Phase 4

Conditions: Acute Coronary Syndrome
Coronary Arteriosclerosis
Myocardial Ischemia
Cardiovascular Diseases

Interventions: Drug: prasugrel
Drug: Clopidogrel

First Posted Date: 2013-01-29

Last Posted Date: 2016-10-21

Lead Sponsor: Arcispedale Santa Maria Nuova-IRCCS

Target Recruit Count: 2000

Registration Number: NCT01777503

Locations: 🇮🇹
Azienda Ospedaliera "Ospedale Civile di Legnano", Legnano, MI, Italy
🇮🇹
Arcispedale Santa Maria Nuova- IRCCS, Reggio Emilia, Italy

Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome

Phase 3

Completed

Conditions: Acute Coronary Syndrome
Unstable Angina

Interventions: Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2013-01-24

Last Posted Date: 2015-06-11

Lead Sponsor: University of Cologne

Target Recruit Count: 49

Registration Number: NCT01774838

Locations: 🇩🇪
Cardiology, University Hospital of Cologne, Cologne, Germany

Platelet Inhibition in Patients With Systolic Heart Failure

Phase 4

Completed

Conditions: Systolic Heart Failure

Interventions: Drug: Prasugrel 10 mg daily x 2 weeks
Drug: Clopidogrel 75 mg daily x 2 weeks

First Posted Date: 2013-01-10

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT01765400

Locations: 🇺🇸
University of Nebaska Medical Center, Omaha, Nebraska, United States

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Procedure: Coronary stenting
Drug: Ticagrelor
Drug: Clopidogrel
Drug: Prasugrel

First Posted Date: 2012-10-04

Last Posted Date: 2016-09-07

Lead Sponsor: Johannes Gutenberg University Mainz

Target Recruit Count: 126

Registration Number: NCT01700322

Locations: 🇩🇪
2 Medical Clinic, Mainz, Germany

A Study of Prasugrel in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Prasugrel ODT2 - Tablet
Drug: Prasugrel ODT1 - Tablet
Drug: Prasugrel ODT2 - Suspension

First Posted Date: 2012-07-24

Last Posted Date: 2013-11-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01648790

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States